Ensysce Biosciences Yönetim

Yönetim kriter kontrolleri 4/4

Ensysce Biosciences CEO'su D. Kirkpatrick, Jan2009 tarihinde atandı, in görev süresi 15.83 yıldır. in toplam yıllık tazminatı $ 508.58K olup, şirket hissesi ve opsiyonları dahil olmak üzere 79.6% maaş ve 20.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.011% ine doğrudan sahiptir ve bu hisseler $ 1.03K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.9 yıl ve 4.3 yıldır.

Anahtar bilgiler

D. Kirkpatrick

İcra Kurulu Başkanı

US$508.6k

Toplam tazminat

CEO maaş yüzdesi	79.6%
CEO görev süresi	15.8yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	4.9yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

Ensysce Biosciences secures $8M convertible note financing

Jul 01

CEO Tazminat Analizi

D. Kirkpatrick'un ücretlendirmesi Ensysce Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	n/a	n/a	-US$12m
Dec 31 2023	US$509k	US$405k	-US$11m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$623k	US$393k	-US$25m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$31m
Dec 31 2021	US$288k	US$174k	-US$30m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$99k
Mar 31 2021	n/a	n/a	US$172k
Dec 31 2020	US$156k	US$156k	US$57k

Tazminat ve Piyasa: D. 'ın toplam tazminatı ($USD 508.58K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 655.02K ).

Tazminat ve Kazançlar: D. 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

D. Kirkpatrick (67 yo)

15.8yrs

Görev süresi

US$508,575

Tazminat

Dr. D. Lynn Kirkpatrick, Ph.D. is a Co Founder of ProlX Pharmaceuticals Corporation and has been its Chief Executive Officer since 1999. She has been Chief Executive Officer of Ensysce Biosciences, Inc. si...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
D. Kirkpatrick	President	15.8yrs	US$508.58k	0.011% $ 1.0k
David Humphrey	CFO, Secretary & Treasurer	3.8yrs	US$441.95k	0.0015% $ 135.2
Geoffrey Birkett	Chief Commercial Officer	6.1yrs	US$392.35k	0% $ 0
Jeffrey Millard	Chief Operating Officer	1.1yrs	Veri yok	Veri yok
William Schmidt	Chairman of Clinical Advisory Board & Chief Medical Officer	8.8yrs	Veri yok	Veri yok
Linda Pestano	Chief Development Officer	3.1yrs	Veri yok	0% $ 0

4.9yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: ENSC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
D. Kirkpatrick	President	7.5yrs	US$508.58k	0.011% $ 1.0k
William Schmidt	Chairman of Clinical Advisory Board & Chief Medical Officer	2.2yrs	Veri yok	Veri yok
Robert Gower	Independent Chairman of the Board	16.8yrs	US$47.60k	0.88% $ 79.2k
Lee Rauch	Independent Director	2.8yrs	US$29.17k	0% $ 0
Andrew Benton	Independent Director	4.9yrs	US$30.10k	0.14% $ 13.0k
Richard Dart	Member of the Clinical Advisory Board	no data	Veri yok	Veri yok
Steven Martin	Independent Director	4.3yrs	US$32.92k	0% $ 0
Lynn Webster	Member of the Clinical Advisory Board	no data	Veri yok	Veri yok
Hui-Chung Chang	Independent Director	8.8yrs	US$30.10k	0.23% $ 20.3k
Jeffrey Gudin	Member of the Clinical Advisory Board	no data	Veri yok	Veri yok
Curtis Rosebraugh	Independent Director	3.4yrs	US$25.42k	0% $ 0
Adam Levin	Independent Director	3.4yrs	US$27.92k	0% $ 0

4.3yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ENSC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Ensysce Biosciences Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ensysce Biosciences, Inc., Annual General Meeting, Nov 21, 2024

Ensysce Biosciences, Inc., Annual General Meeting, Aug 24, 2023

Independent Chairman of the Board recently bought US$182k worth of stock

High number of new directors

Ensysce Biosciences, Inc. Announces Chief Medical Officer Changes

Independent Chairman of the Board notifies of intention to sell stock

Recent updates

Ensysce Biosciences, Inc., Annual General Meeting, Nov 21, 2024

Ensysce Biosciences, Inc. Submits Phase 3 Protocol to the FDA

Price target decreased by 32% to US$9.05

Ensysce Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $1.669895 million.

Ensysce Biosciences, Inc. Announces IRB Approval for Key MPAR Study

Consensus revenue estimates decrease by 25%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 26%, EPS upgraded

No longer forecast to breakeven

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 16% to US$13.50

Ensysce Biosciences Receives Notice from The Nasdaq Stock Market Regarding Non-Compliance with Nasdaq Listing Rule 5550(a)(2)

Consensus EPS estimates fall by 32%

Price target decreased by 16% to US$11.33

Forecast to breakeven in 2026

Full year 2023 earnings released

Price target decreased by 13% to US$11.65

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

New minor risk - Profitability

Price target decreased by 13% to US$11.65

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

Ensysce Biosciences, Inc. has filed a Follow-on Equity Offering.

Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic

New major risk - Share price stability

Ensysce Biosciences, Inc. announced that it has received $1.7 million in funding

Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq

Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study

Consensus revenue estimates decrease by 21%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ensysce Biosciences, Inc. announced that it expects to receive $1.7 million in funding

Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study

Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol

Ensysce Biosciences, Inc., Annual General Meeting, Aug 24, 2023

Ensysce Biosciences Regains Compliance with the Equity Requirement in Nasdaq Listing Rule 5550(b)(1)

Consensus EPS estimates upgraded to US$9.75 loss, revenue downgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering.

Consensus revenue estimates increase by 14%

Price target decreased by 58% to US$29.40

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Chairman of the Board recently bought US$182k worth of stock

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $3.000002 million.

Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq

Ensysce Biosciences, Inc. Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study

Ensysce Biosciences, Inc. Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial

Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection

Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq

Consensus forecasts updated

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.06 million.

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.06 million.

Ensysce Biosciences Inc. Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

Consensus revenue estimates fall by 33%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$240

High number of new directors

Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for Pf614

Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, A TAAP Abuse-Deterrent Oxycodone Extended-Release Product

Ensysce Biosciences, Inc. Announces First Subjects Dosed in Second Human Abuse Potential Study

Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR

Ensysce Biosciences, Inc. Announces Chief Medical Officer Changes

Ensysce Biosciences and Quotient Sciences Announce A Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, A Novel Opioid Designed to Prevent Abuse and Overdose

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Ensysce Biosciences, Inc. announced that it has received $8 million in funding

Independent Chairman of the Board notifies of intention to sell stock

Ensysce Biosciences secures $8M convertible note financing

Ensysce Biosciences, Inc. Appoints William Chang as Director